article thumbnail

QMS market to value nearly $4b by 2030

European Pharmaceutical Review

billion by 2030. Since most pharmaceutical manufacturers export their products to North America and Europe, the need for documents such as process management, corrective and preventive actions (CAPA), deviations, training, quality management, and product release documents is vital.

article thumbnail

Vision for consultant pharmacists by 2030 unveiled by RPS

Hospital Pharmacy Europe

The vision sets out a multifaceted approach under five strategic pillars to help to ensure consultant pharmacists are an integral part of the pharmacy and wider healthcare team in all sectors of the UK by 2030. The post Vision for consultant pharmacists by 2030 unveiled by RPS appeared first on Hospital Pharmacy Europe.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Hidden Risks in RPM Billing: What Every US Healthcare Practice Should Know in 2025

PharmD Live

By 2025, over 71 million Americans (26% of the population) are expected to use RPM services, with the US market projected to double to $29+ billion by 2030. Proven Track Record: Documented success, strong references, and positive client outcomes. billion by 2030 with 12.8% OEI-02-23-00260). link] MarketsandMarkets.

article thumbnail

Tower Cold Chain Submits Its First-Ever Sustainability Report

Pharmaceutical Commerce

The document reiterates the company’s commitment to ESG principles, including carbon neutrality by 2030.

article thumbnail

STAT+: Pharmalittle: Woodcock to retire from the FDA; Acrotech urged to speed up confirmatory study of cancer drugs

STAT

 The company’s final study plan was submitted to the FDA in 2022 and is expected to be completed  by 2030 , according to FDA briefing documents published earlier this week. They were approved under the FDA accelerated pathway in 2009 and 2014, respectively, for treating a rare form of blood cancer. The

FDA 102
article thumbnail

First COVID-19 impact report on global vaccine markets

European Pharmaceutical Review

The document showed that in 2021, approximately 16 billion vaccine doses, worth $141 billion, were supplied across 47 vaccines and 94 manufacturers. Achieving Immunization Agenda 2030 goals. WHO is calling for much-needed changes to the global vaccine market to save lives, prevent disease and prepare for future crises.”

article thumbnail

Navigating the regulatory challenge of PFAS for pharmaceutical manufacturers

European Pharmaceutical Review

In the EU, a joint PFAS Restriction Proposal under REACH was submitted, aiming for a full ban by 2028/2030. billion Global concerns surrounding PFAS, or per- and polyfluoroalkyl substances, are due to their well-documented effects on human health and the environment. There is worldwide concern around the use of PFAS.